Loading...
Market
What will be Element Biosciences' market share in the DNA sequencing market by the end of 2024?
3
Resolution / Starting Odds
Below 5% • 25%
5%-10% • 25%
10%-15% • 25%
Above 15% • 25%
Market research reports, industry analysis reports
Story
Element Biosciences Raises $277 Million in Series D Venture Funding
Jul 12, 2024, 01:13 PM
Element Biosciences, a San Diego-based company specializing in next-generation sequencing (NGS), has successfully raised $277 million in a Series D venture funding round. The investment will enable the company to continue commercializing its AVITI benchtop genomic analyzer and launch its next product, AVITI24. This significant funding round positions Element Biosciences as a formidable competitor to Illumina in the DNA sequencing market. The company aims to leverage this capital to solidify its presence and drive rapid growth in the biotechnology sector.
View original story
Similar markets
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No change • 25%
Decrease • 25%
Yes • 50%
No • 50%
0-10% • 25%
11-25% • 25%
26-50% • 25%
51%+ • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Market share increases • 25%
Market share remains the same • 25%
Market share decreases • 25%
Foresight exits cancer-detection market • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
New test leads market • 25%
Existing tests maintain dominance • 25%
Market share evenly distributed • 25%
Other outcome • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%